

# News Release



Japan Credit Rating Agency, Ltd.

25-D-1347

February 6, 2026

Japan Credit Rating Agency, Ltd. (JCR) announces the following credit rating.

## The Takeda Healthcare Foundation (security code: -)

<Outlook Change>

Long-term Issuer Rating: A-

Outlook: from Stable to Negative

### Rationale

- (1) The Takeda Healthcare Foundation (the "Foundation") is a general incorporated foundation, operating two hospitals in Aizuwakamatsu City, Fukushima Prefecture. Its mainstay Takeda General Hospital (the "Hospital") with 827 beds mainly engages in acute medical care and is the core hospital in the medical care zones of Aizu and Minamiaizu, as indicated by its designation as a community medical support hospital, a regional cooperative core hospital of cancer treatment and a perinatal medical center. Ashinomaki Onsen Hospital with 120 beds provides chronic care. Other than these hospitals, the Foundation runs geriatric health services facilities, multifunctional long-term care in a small group homes and other facilities, thereby providing comprehensive community-based services covering fields from acute care to nursing care and welfare.
- (2) The Foundation maintains its business base in the Aizu area but is taking longer time than expected in shifting to an earnings structure adapted to changes in the business environment. Amid weakening medical demand, the deterioration of the business environment is extremely severe, as shown by a sharp rise in various expenses. While achieving certain results in its efforts to raise the bed occupancy rate and the unit price of medical care at the Hospital, the Foundation has not been able to secure sufficient cash flow since the fiscal year ended March 2024 (FY2023). On the other hand, borrowings are not large, and near-term investment expenditures are expected to be restrained, meaning that no major financial issues have arisen. Based on the above, JCR, while affirming the rating on the Foundation, changed the outlook to Negative. Whether the Foundation can secure certain cash flow partly through the government's support measures in the medical and nursing care areas will be closely monitored to be reflected in the future rating decisions.
- (3) The Hospital is undertaking such initiatives as: expanding emergency care capacity to secure inpatients; shortening hospital stays through the strengthened regional collaboration including downstream transfers and so forth; and appropriately calculating additional fees and guidance fees. Medical revenue is improving thanks in part to a rise in the unit price of medical care through these initiatives. That said, because of rising personnel and other expenses, securing a greater number of new inpatients has become crucial to improve earnings. FY2025 supplementary budget and FY2026 medical fee revisions indicate the government's stance to support medical care and nursing care. JCR will watch whether the above initiatives, in addition to the Hospital's improvement measures, will have a full effect on restoring income-expenditure balance.
- (4) Net assets have decreased because of recent years' tough earnings situation, thus weakening the financial structure. Yet, the repayment of loans financed for the construction of the Hospital is progressing, reducing the repayment burden compared to before. As regards the rebuilding of Ashinomaki Onsen Hospital at a new location, it will likely be carefully decided in light of surging construction costs and so forth. Even though the aging of facilities at this hospital requires attention, the investment burden is not likely to increase for the time being.

Yosuke Sato, Tadashi Ono

### Rating

Issuer: The Takeda Healthcare Foundation

<Outlook Change>

Long-term Issuer Rating: A-

Outlook: Negative

**Rating Assignment Date: February 3, 2026**

The assumptions for the credit ratings and the definitions of the rating symbols are published as "Types of Credit Ratings and Definitions of Rating Symbols" (January 6, 2014) in Information about JCR Ratings on JCR's website (<https://www.jcr.co.jp/en/>).

Outline of the rating methodology is shown as "JCR's Rating Methodology" (October 1, 2024) and "Medical Institutions" (August 1, 2023) in Information about JCR Ratings on JCR's website (<https://www.jcr.co.jp/en/>).

The rating stakeholder participated in the rating process of the aforementioned credit ratings.

**Japan Credit Rating Agency, Ltd.**

Jiji Press Building, 5-15-8 Ginza, Chuo-ku, Tokyo 104-0061, Japan

Tel. +81 3 3544 7013, Fax. +81 3 3544 7026

Information herein has been obtained by JCR from the issuers and other sources believed to be accurate and reliable. However, because of the possibility of human or mechanical error as well as other factors, JCR makes no representation or warranty, express or implied, as to accuracy, results, adequacy, timeliness, completeness or merchantability, or fitness for any particular purpose, with respect to any such information, and is not responsible for any errors or omissions, or for results obtained from the use of such information. Under no circumstances will JCR be liable for any special, indirect, incidental or consequential damages of any kind caused by the use of any such information, including but not limited to, lost opportunity or lost money, whether in contract, tort, strict liability or otherwise, and whether such damages are foreseeable or unforeseeable. JCR's ratings and credit assessments are statements of JCR's current and comprehensive opinion regarding redemption possibility, etc. of financial obligations assumed by the issuers or financial products, and not statements of opinion regarding any risk other than credit risk, such as market liquidity risk or price fluctuation risk. JCR's ratings and credit assessments are statements of opinion, and not statements of fact as to credit risk decisions or recommendations regarding decisions to purchase, sell or hold any securities such as individual bonds or commercial paper. The ratings and credit assessments may be changed, suspended or withdrawn as a result of changes in or unavailability of information as well as other factors. JCR receives a rating fee paid by issuers for conducting rating services in principle. JCR retains all rights pertaining to this document, including JCR's rating data. Any reproduction, adaptation, alteration, etc. of this document, including such rating data, is prohibited, whether or not wholly or partly, without prior consent of JCR.

JCR is registered as a "Nationally Recognized Statistical Rating Organization" with the U.S. Securities and Exchange Commission with respect to the following four classes. (1) Financial institutions, brokers and dealers, (2) Insurance Companies, (3) Corporate Issuers, (4) Issuers of government securities, municipal securities and foreign government securities.

JCR publishes its press releases regarding the rating actions both in Japanese and in English on the same day. In case that it takes time to translate rating rationale, JCR may publicize the summary version, which will be replaced by the full translated version within three business days. (Regarding Structured Finance products, JCR only publicize the summary version in English.)